In addition, M2 TAMs express SR-A, as an ApoA-I analog, a small peptide inhibitor (D-amino acid peptide), can be used for targeted treatment in vivo to block SRA-mediated adhesion of TAMs and prevent tumor progression and distant metastasis [69]. Here, APOA1 is linked to neoplasm.